Project Grant R01AI195642
Award Date 9/3/26
Completion Date 8/31/31
Dollars Obligated $558K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19107, USA
Similar Awards
- Federal Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $156,000 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded on July 14, 2025, with an ultimate completion date of June 30, 2027. The award supports biomedical research focused on characterizing homotypic fusion mechanisms in Chlamydia muridarum, a surrogate model for understanding...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $717,952 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate host lipid acquisition and the maintenance of the Chlamydia replicative niche. The research addresses Chlamydia trachomatis infection, the leading cause of bacterial sexually transmitted infections, for which no vaccine exists. The project will test the hypothesis that a single...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of California Irvine $760,663 on August 7, 2026, for a Project Grant (R01AI202117) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will conduct research into the regulatory mechanisms controlling production of infectious elementary bodies (EBs) in Chlamydia trachomatis, the causative agent of the most commonly reported...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Idaho $505,406 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cell form determination during the chlamydial intracellular infectious cycle. The award funds research into the mechanisms regulating distinct developmental cell forms—the reticulate body (RB),...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Virginia a Project Grant of $450,766 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 8, 2025, with completion targeted for July 31, 2027. This research initiative aims to characterize how Chlamydia trachomatis, the leading cause of bacterial sexually transmitted infections, remodels inter-organelle communication within host cells to create a...
- The National Institute of Allergy and Infectious Diseases awarded $435,875 to Trustees of Indiana University (Indiana University Indianapolis) on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how Chlamydia-infected cells affect non-infected bystander host cells and identify intervention points that could promote clearance of Chlamydia trachomatis without broad-spectrum antibiotics. The research addresses the mechanisms underlying...
- The National Institute of Allergy and Infectious Diseases awarded the Board of Regents of the University of Nebraska $417,845 on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate post-translational modulation of host purine biosynthetic enzymes by Chlamydia trachomatis. The project, designated R21AI199320, examines how Chlamydia trachomatis, an obligate intracellular bacterium, manipulates host cell GTP biosynthesis to support its own growth....
- The National Institute of Allergy and Infectious Diseases awarded Thomas Jefferson University $235,500 on July 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the molecular factors governing the biogenesis and release of short immunostimulatory RNAs. The research addresses the role of transfer RNA-derived short non-coding RNAs (tRNA-derived sncRNAs), particularly 5-tRNA halves, in host defense against microbial pathogens. The project...
- The National Institute of Allergy and Infectious Diseases awarded The University of Iowa $2,882,765 on June 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how Chlamydia trachomatis effector proteins disrupt centrosome function and promote cellular transformation events associated with oncogenesis. The research addresses mechanisms by which C. trachomatis, the leading cause of non-congenital blindness and the most prevalent sexually transmitted...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Davis $404,570 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and validate target antigens recognized by protective Chlamydia-specific memory CD4 T cells and to examine whether an mRNA vaccine approach can provide protection in a mouse model. This work addresses antigen identification for Chlamydia vaccine development; Chlamydia trachomatis...